Skip to main content
Title Pub Year Author Sort ascending SearchLink
Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey 2000 Division of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. slt4@cdc.gov
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Journal of periodontology
Periodical, Abbrev.
J.Periodontol.
Pub Date Free Form
May
Volume
71
Issue
5
Start Page
743
Other Pages
751
Notes
LR: 20041117; JID: 8000345; ppublish
Place of Publication
UNITED STATES
ISSN/ISBN
0022-3492; 0022-3492
Accession Number
PMID: 10872955
Language
eng
SubFile
Journal Article; D; IM
DOI
10.1902/jop.2000.71.5.743 [doi]
Output Language
Unknown(0)
PMID
10872955
Abstract
BACKGROUND: The principal objectives of this study were to examine the relationship between cigarette smoking and periodontitis and to estimate the proportion of periodontitis in the United States adult population that is attributable to cigarette smoking. METHODS: Data were derived from the Third National Health and Nutrition Examination Survey, a nationally representative multipurpose health survey conducted in 1988 to 1994. Participants were interviewed about tobacco use and examined by dentists trained to use standardized clinical criteria. Analysis was limited to dentate persons aged > or =18 years with complete clinical periodontal data and information on tobacco use and important covariates (n = 12,329). Data were weighted to provide U.S. national estimates, and analyses accounted for the complex sample design. We defined periodontitis as the presence of > or =1 site with clinical periodontal attachment level > or =4 mm apical to the cemento-enamel junction and probing depth > or =4 mm. Current cigarette smokers were those who had smoked > or =100 cigarettes over their lifetime and smoked at the time of the interview; former smokers had smoked > or =100 cigarettes but did not currently smoke; and never smokers had not smoked > or =100 cigarettes in their lifetime. RESULTS: We found that 27.9% (95% confidence interval [CI]: +/-1.8%) of dentate adults were current smokers and 23.3% (95% CI: +/-1.2%) were former smokers. Overall, 9.2% (95% CI: +/-1.4%) of dentate adults met our case definition for periodontitis, which projects to about 15 million cases of periodontitis among U.S. adults. Modeling with multiple logistic regression revealed that current smokers were about 4 times as likely as persons who had never smoked to have periodontitis (prevalence odds ratio [ORp] = 3.97; 95% CI, 3.20-4.93), after adjusting for age, gender, race/ethnicity, education, and income:poverty ratio. Former smokers were more likely than persons who had never smoked to have periodontitis (ORp = 1.68; 95% CI, 1.31-2.17). Among current smokers, there was a dose-response relationship between cigarettes smoked per day and the odds of periodontitis (P or =31 cigarettes per day. Among former smokers, the odds of periodontitis declined with the number of years since quitting, from ORp = 3.22 (95% CI, 2.18-4.76) for 0 to 2 years to ORp = 1.15 (95% CI, 0.83-1.60) for > or =11 years. Applying standard epidemiologic formulas for the attributable fraction for the population, we calculated that 41.9% of periodontitis cases (6.4 million cases) in the U.S. adult population were attributable to current cigarette smoking and 10.9% (1.7 million cases) to former smoking. Among current smokers, 74.8% of their periodontitis was attributable to smoking. CONCLUSIONS: Based on findings from this study and numerous other reports, we conclude that smoking is a major risk factor for periodontitis and may be responsible for more than half of periodontitis cases among adults in the United States. A large proportion of adult periodontitis may be preventable through prevention and cessation of cigarette smoking.
Descriptors
Adolescent, Adult, Aged, Dental Health Surveys, Ethnic Groups, Female, Humans, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Periodontitis/epidemiology/etiology, Prevalence, Smoking/adverse effects/epidemiology, Smoking Cessation/statistics & numerical data, Socioeconomic Factors, United States/epidemiology
Links
Book Title
Database
Publisher
Data Source
Authors
Tomar,S. L., Asma,S.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
A review of the relationship between patent foramen ovale and type II decompression sickness 2001 Division of Occupational Medicine, University of Toronto, Canada. joan.saary@utoronto.ca
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Aviation, Space, and Environmental Medicine
Periodical, Abbrev.
Aviat.Space Environ.Med.
Pub Date Free Form
Dec
Volume
72
Issue
12
Start Page
1113
Other Pages
1120
Notes
LR: 20051116; JID: 7501714; RF: 82; ppublish
Place of Publication
United States
ISSN/ISBN
0095-6562; 0095-6562
Accession Number
PMID: 11763113
Language
eng
SubFile
Journal Article; Review; IM; S
DOI
Output Language
Unknown(0)
PMID
11763113
Abstract
The significance of patent foramen ovale (PFO) in the pathophysiology of Type II decompression sickness (DCS) remains controversial. PFOs are common, occurring in approximately one quarter of the normal population, thus making right-to-left shunting of venous gas emboli (VGE) a theoretical concern in both hyper- and hypobaric situations. Despite this high prevalence of PFO in the general population, and the relatively common occurrence of venous gas bubbles in diving and altitude exposures, the incidence of Type II DCS in diving or with altitude is remarkably low. Although the literature supports a relationship between the presence and size of PFO and cryptogenic stroke, and an increased relative risk of Type II DCS with a PFO in divers, the absolute increase in risk accrued is small. Hence, the value of screening is also controversial. This paper presents a summary of the literature on PFOs and DCS in animals, and in human altitude and diving, focusing on the latter; as well the analogous literature on cryptogenic stroke. The results of an examination of the literature on detection of, screening for, and treatment of PFOs is also presented.
Descriptors
Altitude, Animals, Brain/pathology, Decompression Sickness/etiology/physiopathology, Diving, Echoencephalography, Heart Septal Defects, Atrial/complications/therapy, Humans, Magnetic Resonance Imaging, Military Personnel, Ultrasonography, Doppler
Links
Book Title
Database
Publisher
Data Source
Authors
Saary,M. J., Gray,G. W.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
Identification of the antioxidant principles of Polyalthia longifolia var. pendula using TEAC assay 2011 Division of Medicinal and Process Chemistry, Central Drug Research Institute (CSIR), Uttar Pradesh, India. sashidhar123@gmail.com
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Natural product research
Periodical, Abbrev.
Nat.Prod.Res.
Pub Date Free Form
May
Volume
25
Issue
9
Start Page
918
Other Pages
926
Notes
LR: 20131121; JID: 101167924; 0 (Antioxidants); 0 (Flavonoids); 0 (Glycosides); 9IKM0I5T1E (Quercetin); ppublish
Place of Publication
England
ISSN/ISBN
1478-6427; 1478-6419
Accession Number
PMID: 21547843
Language
eng
SubFile
Journal Article; IM
DOI
10.1080/14786419.2010.490214 [doi]
Output Language
Unknown(0)
PMID
21547843
Abstract
Activity-guided fractionation of the ethanolic extract of the leaves of the Polyalthia longifolia var. pendula led to the identification of quercetin (1), quercetin-3-O-beta-glucopyranoside (2), kaempferol-3-O-alpha-rhamnopyranosyl-(1 --> 6)-beta-galactopyranoside (3), kaempferol-3-O-alpha-rhamnopyranosyl-(1 --> 6)-beta-glucopyranoside (4), rutin (5) and allantoin (6) as the active constituents from the butanol fraction. Compounds 2-4 are reported for the first time from this natural source. Structures of the compounds were confirmed on the basis of their 1D and 2D NMR coupled with other spectroscopic methods. All the isolated compounds and the fractions were evaluated for their antioxidant potential using the TEAC assays and it was found that the activity of the active fraction was due to quercetin (1) and its glycosides (2 and 5), with TEAC values of 4.10, 1.91 and 2.38 mM, respectively, while the kaempferol glycosides were found to be inactive. This is the first study on the antioxidant activity of this plant species.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Sashidhara,K.V., Singh,S.P., Srivastava,A., Puri,A.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
Water Quality Evaluation of PET Bottled Water by Mineral Balance in the Northeast Asian Region: A Case Study of South Korea 2015 Division of Medical Education, Department of Social Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.; daggerFaculty of Economics and International Trade, Kangwon National University, Chuncheon 200-701, South Ko
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Yonago acta medica
Periodical, Abbrev.
Yonago Acta Med.
Pub Date Free Form
Sep
Volume
58
Issue
3
Start Page
115
Other Pages
122
Notes
LR: 20151107; JID: 0414002; OID: NLM: PMC4626357; OTO: NOTNLM; 2015/06/26 [received]; 2015/07/27 [accepted]; 2015/10/14 [epublish]; ppublish
Place of Publication
Japan
ISSN/ISBN
0513-5710; 0513-5710
Accession Number
PMID: 26538797
Language
eng
SubFile
Journal Article
DOI
Output Language
Unknown(0)
PMID
26538797
Abstract
BACKGROUND: The past few years have seen a demand for drinking water in contemporary society with a focus on safety and taste. Mineral water is now marketed as a popular commercial product and, partly due to health concerns, the production. METHODS: For the study, a comparison was carried out of water samples from 9 types of polyethylene terephthalate (PET) bottled water sold in South Korea as well as from tap water in the cities of Seoul and Chuncheon. These were compared with samples of Japanese PET bottled water in order to determine shared commonalities and identify individual characteristics. To evaluate water quality objectively, we quantified the elements contained in the water samples. Samples were assessed not with the usual sensory evaluation but with the evaluation approach advocated by Hashimoto et al. which employs the Water Index of Taste and the Water Index of Health. The levels of water quality obtained were compared with the "Prerequisites for Tasty Water" and the "Standards for Tasty Water" devised for city water. RESULTS: The PET Bottled water varieties analyzed in this study-Seoksu, Icis, Bong Pyong, Soon Soo 100, Dong Won Saem Mul, GI JANG SOO and DIAMOND-showed the Water Index of Taste >/= 2.0 and the Water Index of Health >/= 5.2, which we classified as tasty/healthy water. SamDaSoo and NamiNeral can be classified as tasty water due to their values of the Water Index of Taste >/= 2.0 and the Water Index of Health
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Houri,D., Koo,C.M.
Original/Translated Title
URL
Date of Electronic
20151014
PMCID
PMC4626357
Editors
Quantification of flavor-related compounds in the unburned contents of bidi and clove cigarettes 2006 Division of Laboratory Sciences, Emergency Response and Air Toxicants Branch, National Center for Environmental Health, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3719, USA. sstanfill@cdc.gov
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Journal of Agricultural and Food Chemistry
Periodical, Abbrev.
J.Agric.Food Chem.
Pub Date Free Form
1-Nov
Volume
54
Issue
22
Start Page
8580
Other Pages
8588
Notes
LR: 20151119; JID: 0374755; 0 (Flavoring Agents); ppublish
Place of Publication
United States
ISSN/ISBN
0021-8561; 0021-8561
Accession Number
PMID: 17061837
Language
eng
SubFile
Journal Article; IM
DOI
10.1021/jf060733o [doi]
Output Language
Unknown(0)
PMID
17061837
Abstract
Bidi cigarettes, small hand-rolled cigarettes produced primarily in India, are sold in the United States in a wide variety of candy-like flavors (e.g. dewberry, chocolate, clove) and are popular with adolescents. Many flavored bidis contain high concentrations of compounds such as eugenol, anethole, methyleugenol, pulegone, and estragole; several of these compounds have known toxic or carcinogenic properties. Clove cigarettes, or kreteks, are another highly flavored tobacco product with high levels of eugenol due to clove buds present in the tobacco filler. In this study, compounds in the burnable portion-the filler and wrapper material actually consumed during the smoking of bidis, kreteks, and U.S. cigarettes-were analyzed. Flavor-related compounds were solvent extracted from the burnable portion of each cigarette with methanol. An aliquot of the methanol extract was heated, and the sample headspace was sampled with a solid-phase microextraction fiber and introduced into a gas chromatograph-mass spectrometer for analysis in selected-ion monitoring mode. High levels of eugenol were detected in five clove-flavored bidi brands ranging from 78.6 to 7130 microg/cigarette (microg/cig), whereas diphenyl ether (128-3550 microg/cig) and methyl anthranilate (154-2360 microg/cig) were found in one grape-flavored bidi brand. A nontobacco herbal bidi brand contained the greatest variety of compounds, including anethole (489-665 microg/cig), eugenol (1670-2470 microg/cig), methyleugenol (27.7-36.6 microg/cig), safrole (32.4-34.4 microg/cig), myristicin (170-247 microg/cig), and elemicin (101-109 microg/cig). Filler from kreteks was found to contain high levels of eugenol, anethole, and coumarin. Flavored bidis and clove cigarettes contain a number of compounds that are present at levels far exceeding those reported in U.S. cigarette tobacco. Research is underway to determine the levels of these compounds delivered in smoke. It is not known what effect inhalation of these compounds has on smokers.
Descriptors
Filtration, Fires, Flavoring Agents/analysis/chemistry, Mass Spectrometry, Reproducibility of Results, Syzygium/chemistry, Tobacco/chemistry
Links
Book Title
Database
Publisher
Data Source
Authors
Stanfill,S. B., Brown,C. R., Yan,X. J., Watson,C. H., Ashley,D. L.
Original/Translated Title
URL
Date of Electronic
PMCID
Editors
Prevalence and Predictors of Gastroesophageal Reflux Complications in Community Subjects 2016 Division of Internal Medicine, Mayo Clinic, Rochester, MN, USA.; Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.; Division of Biomedical Statistics and Informatics, Mayo Clinic,
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Digestive diseases and sciences
Periodical, Abbrev.
Dig.Dis.Sci.
Pub Date Free Form
10-Aug
Volume
Issue
Start Page
Other Pages
Notes
LR: 20160811; JID: 7902782; OTO: NOTNLM; 2016/04/19 [received]; 2016/07/22 [accepted]; 2016/08/10 [aheadofprint]; aheadofprint
Place of Publication
ISSN/ISBN
1573-2568; 0163-2116
Accession Number
PMID: 27510751
Language
ENG
SubFile
JOURNAL ARTICLE
DOI
10.1007/s10620-016-4266-3 [doi]
Output Language
Unknown(0)
PMID
27510751
Abstract
BACKGROUND: Predictors of erosive esophagitis (EE) and Barrett's esophagus (BE) and the influence of number of risk factors in the community are not well defined. METHODS: Rates of BE and EE among community residents identified in a randomized screening trial were defined. The risk of EE and BE associated with single and multiple risk factors (gender, age, GERD, Caucasian ethnicity, ever tobacco use, excess alcohol use, family history of BE or EAC, and central obesity) was analyzed. RESULTS: Sixty-eight (33 %) of 205 subjects had EE and/or BE. BE prevalence was 7.8 % with dysplasia present in 1.5 %. Rates were comparable between subjects with and without GERD. Male sex and central obesity were independent risk factors. The odds of EE or BE were 3.7 times higher in subjects with three or four risk factors and 5.7 times higher in subjects with five or more risk factors compared with those with two or less factors. CONCLUSIONS: EE and BE are prevalent in the community regardless of the presence of GERD. Risk appeared to be additive, increasing substantially with three or more risk factors.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Crews,N.R., Johnson,M.L., Schleck,C.D., Enders,F.T., Wongkeesong,L.M., Wang,K.K., Katzka,D.A., Iyer,P.G.
Original/Translated Title
URL
Date of Electronic
20160810
PMCID
Editors
In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms 2009 Division of Infectious Diseases, University of New Mexico Health Science Center, Albuquerque, NM 87108, USA.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
International journal of antimicrobial agents
Periodical, Abbrev.
Int.J.Antimicrob.Agents
Pub Date Free Form
Oct
Volume
34
Issue
4
Start Page
326
Other Pages
332
Notes
LR: 20140603; GR: T32 AI007538/AI/NIAID NIH HHS/United States; JID: 9111860; 0 (Antifungal Agents); 0 (Echinocandins); 7XU7A7DROE (Amphotericin B); 8VZV102JFY (Fluconazole); F0XDI6ZL63 (caspofungin); N12000U13O (Doxycycline); 2009/01/18 [received]; 2009/0
Place of Publication
Netherlands
ISSN/ISBN
1872-7913; 0924-8579
Accession Number
PMID: 19515537
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; IM
DOI
10.1016/j.ijantimicag.2009.04.011 [doi]
Output Language
Unknown(0)
PMID
19515537
Abstract
The potential of antifungal agents used as antimicrobial lock therapy (ALT) for the conservative management of catheter-related candidemia has not been fully defined. We sought to determine the antifungal effect of high-dose doxycycline (DOX), alone or in combination with standard concentrations of amphotericin B (AMB), caspofungin (CAS) or fluconazole (FLC), against biofilms formed by Candida albicans in vitro. DOX alone (at 2048 microg/mL and 1024 microg/mL) demonstrated up to an 85% reduction of the metabolic activity of the C. albicans biofilm. Regardless of the concentration tested, FLC alone showed minimal activity (mean 22.9% reduction) against the C. albicans biofilm. When DOX 2048 microg/mL was used in combination with FLC, antifungal activity also increased up to 85%, suggesting an additive effect. DOX 128 microg/mL in combination with FLC demonstrated synergy (mean 58.3% reduction). The combination of DOX 2048 microg/mL or 512 microg/mL and AMB was superior to AMB alone at low concentrations (0.25-0.03125 microg/mL). However, DOX 128 microg/mL was antagonistic in combination with low concentrations of AMB. Maximal efficacy against the biofilm was observed with CAS at 8-0.25 microg/mL compared with FLC and AMB alone. A paradoxical effect (PE) occurred with CAS at 16 microg/mL, which showed a marked reduction in antifungal activity compared with lower concentrations of CAS. CAS at 16 microg/mL in combination with either DOX 2048 microg/mL or 512 microg/mL resulted in attenuation of the PE. These findings suggest that a high-dose DOX-based ALT strategy in combination with traditional antifungal agents may be useful for the treatment of C. albicans biofilms.
Descriptors
Amphotericin B/pharmacology, Antifungal Agents/pharmacology, Biofilms/drug effects, Candida albicans/drug effects, Dose-Response Relationship, Drug, Doxycycline/administration & dosage/pharmacology, Drug Interactions, Drug Therapy, Combination, Echinocandins/pharmacology, Fluconazole/pharmacology, Humans, Microbial Sensitivity Tests
Links
Book Title
Database
Publisher
Data Source
Authors
Miceli,M. H., Bernardo,S. M., Lee,S. A.
Original/Translated Title
URL
Date of Electronic
20090609
PMCID
Editors
Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species 2007 Division of Infectious Diseases, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Antimicrobial Agents and Chemotherapy
Periodical, Abbrev.
Antimicrob.Agents Chemother.
Pub Date Free Form
Sep
Volume
51
Issue
9
Start Page
3081
Other Pages
3088
Notes
LR: 20140904; JID: 0315061; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Tetrazolium Salts); 117038-70-7 (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2H-tetrazoliu m hydroxide); F0XDI6ZL63 (caspofungin); OID: NLM: PMC2043224; 2007/0
Place of Publication
United States
ISSN/ISBN
0066-4804; 0066-4804
Accession Number
PMID: 17591847
Language
eng
SubFile
Journal Article; IM
DOI
AAC.00676-07 [pii]
Output Language
Unknown(0)
PMID
17591847
Abstract
The paradoxical growth (PG) of Candida sp. biofilms in the presence of high caspofungin (CAS) concentrations was previously unknown. We sought to characterize the PG at supra-MICs of CAS among clinical Candida sp. isolates grown as biofilms in 96-well polystyrene microtiter plates. The MICs of CAS were determined for 30 clinical Candida sp. isolates (4 Candida albicans, 6 C. tropicalis, 7 C. parapsilosis, 8 C. orthopsilosis, and 5 C. metapsilosis isolates) when they were grown as planktonic cells and biofilms and were defined as the lowest drug concentrations that resulted in a prominent decrease in growth and a 50% reduction in metabolic activity, respectively. PG was defined as a resurgence of growth (>50% of that in the drug-free growth control well) at drug concentrations above the MIC. With the exception of C. tropicalis, all isolates displayed PG more frequently when they were grown as biofilms than when they grown as planktonic cells. PG was undetectable among C. metapsilosis isolates in planktonic cell MIC tests but was present in 100% of the isolates in biofilm MIC tests. The drug concentration and the number of drug dilutions supporting PG were higher for biofilms than for planktonic cells. Microscopic changes in cell morphology were observed among both planktonic and biofilm cells with PG. Specifically, the accumulation of enlarged, globose cells was associated with PG, and we hypothesize that CAS-induced changes in the cell wall composition may be the explanation.
Descriptors
Antifungal Agents/pharmacology, Biofilms/drug effects, Candida/drug effects/growth & development/physiology, Candidiasis/microbiology, Echinocandins/pharmacology, Microbial Sensitivity Tests, Risk, Tetrazolium Salts
Links
Book Title
Database
Publisher
Data Source
Authors
Melo,A. S., Colombo,A. L., Arthington-Skaggs,B. A.
Original/Translated Title
URL
Date of Electronic
20070625
PMCID
PMC2043224
Editors
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins 2002 Division of Infectious Diseases, Department of Medicine, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio 44106, USA.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Antimicrobial Agents and Chemotherapy
Periodical, Abbrev.
Antimicrob.Agents Chemother.
Pub Date Free Form
Jun
Volume
46
Issue
6
Start Page
1773
Other Pages
1780
Notes
LR: 20140612; GR: AI-36219/AI/NIAID NIH HHS/United States; GR: AI07024/AI/NIAID NIH HHS/United States; GR: AI35097-03/AI/NIAID NIH HHS/United States; GR: P30 CA43703-12/CA/NCI NIH HHS/United States; JID: 0315061; 0 (Anti-Bacterial Agents); 0 (Antifungal A
Place of Publication
United States
ISSN/ISBN
0066-4804; 0066-4804
Accession Number
PMID: 12019089
Language
eng
SubFile
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; IM
DOI
Output Language
Unknown(0)
PMID
12019089
Abstract
Biofilms, likely the predominant mode of device-related microbial infection, exhibit resistance to antimicrobial agents. Evidence suggests that Candida biofilms have dramatically reduced susceptibility to antifungal drugs. We examined antifungal susceptibilities of Candida albicans and Candida parapsilosis biofilms grown on a bioprosthetic model. In addition to conventional agents, we determined if new antifungal agents (triazoles, amphotericin B lipid formulations, and echinocandins) have activities against Candida biofilms. We also explored effects of preincubation of C. albicans cells with subinhibitory concentrations (sub-MICs) of drugs to see if they could modify subsequent biofilm formation. Finally, we used confocal scanning laser microscopy (CSLM) to image planktonic- and biofilm-exposed blastospores to examine drug effects on cell structure. Candida biofilms were formed on silicone elastomer and quantified by tetrazolium and dry weight (DW) assays. Susceptibility testing of fluconazole, nystatin, chlorhexidine, terbenafine, amphotericin B (AMB), and the triazoles voriconazole (VRC) and ravuconazole revealed resistance in all Candida isolates examined when grown as biofilms, compared to planktonic forms. In contrast, lipid formulations of AMB (liposomal AMB and AMB lipid complex [ABLC]) and echinocandins (caspofungin [Casp] and micafungin) showed activity against Candida biofilms. Preincubation of C. albicans cells with sub-MIC levels of antifungals decreased the ability of cells to subsequently form biofilm (measured by DW; P < 0.0005). CSLM analysis of planktonic and biofilm-associated blastospores showed treatment with VRC, Casp, and ABLC resulted in morphological alterations, which differed with each agent. In conclusion, our data show that Candida biofilms show unique susceptibilities to echinocandins and AMB lipid formulations.
Descriptors
Amphotericin B/administration & dosage/pharmacology, Anti-Bacterial Agents/pharmacology, Antifungal Agents/administration & dosage/pharmacology, Biofilms/drug effects, Candida/drug effects/ultrastructure, Culture Media, Drug Resistance, Microbial, Echinocandins, Fungal Proteins, Liposomes, Microbial Sensitivity Tests, Microscopy, Confocal, Peptides, Peptides, Cyclic, Polyenes/pharmacology, Prosthesis-Related Infections/microbiology, Triazoles/pharmacology
Links
Book Title
Database
Publisher
Data Source
Authors
Kuhn,D. M., George,T., Chandra,J., Mukherjee,P. K., Ghannoum,M. A.
Original/Translated Title
URL
Date of Electronic
PMCID
PMC127206
Editors
In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates 2007 Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Diagnostic microbiology and infectious disease
Periodical, Abbrev.
Diagn.Microbiol.Infect.Dis.
Pub Date Free Form
Mar
Volume
57
Issue
3
Start Page
277
Other Pages
281
Notes
LR: 20141120; JID: 8305899; 0 (Antifungal Agents); 0 (Echinocandins); 0 (Peptides, Cyclic); 0 (Pyrimidines); 0 (Triazoles); F0XDI6ZL63 (caspofungin); JFU09I87TR (Voriconazole); 2006/08/04 [received]; 2006/09/12 [revised]; 2006/09/15 [accepted]; 2006/12/01
Place of Publication
United States
ISSN/ISBN
0732-8893; 0732-8893
Accession Number
PMID: 17141454
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
S0732-8893(06)00370-1 [pii]
Output Language
Unknown(0)
PMID
17141454
Abstract
Thirty clinical isolates of Candida albicans were collected from blood or other sterile site infections. Biofilm dry weight and metabolic activity were measured for each isolate. Planktonic and sessile antifungal susceptibilities of each isolate were determined for amphotericin B deoxycholate, caspofungin, and voriconazole. Sessile susceptibilities were determined for the combination of caspofungin/voriconazole. No significant differences in biofilm dry weight or metabolic activity were found between bloodstream and other invasive isolates. Planktonic MIC90 values and sessile MIC90 (SMIC90) values were 0.25 and 2, 0.06 and >256, and 0.5 and 2 microg/mL for amphotericin, voriconazole, and caspofungin, respectively. The SMIC90 of the combination of caspofungin/voriconazole against sessile isolates was 0.5/2 microg/mL. Therefore, the source of invasive C. albicans clinical isolates did not affect in vitro biofilm formation. Susceptibility to antifungal agents decreased when C. albicans was associated with biofilm, and the combination of caspofungin/voriconazole did not appear to provide enhanced activity compared with caspofungin alone.
Descriptors
Antifungal Agents/pharmacology, Biofilms/drug effects, Candida albicans/drug effects/physiology, Drug Therapy, Combination, Echinocandins, Humans, Microbial Sensitivity Tests/methods, Peptides, Cyclic/pharmacology, Pyrimidines/pharmacology, Triazoles/pharmacology, Voriconazole
Links
Book Title
Database
Publisher
Data Source
Authors
Shuford,J. A., Piper,K. E., Steckelberg,J. M., Patel,R.
Original/Translated Title
URL
Date of Electronic
20061201
PMCID
Editors